- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | CDC panel votes to scrap hepatitis B birth dose advice | ||
| Fr | Praxis soars on rare childhood epilepsy trial data | ||
| Fr | Protego's $130m for amyloidosis drug, and other financings | ||
| Fr | BMS's Breyanzi is first CAR-T for marginal zone lymphoma | ||
| Fr | Setback for MSD as German court blocks Keytruda SC launch | ||
| Fr | NHS use of digital cardiac rehab tools endorsed | ||
| Do | NHS staff 'feel unprepared for digital transformation' | ||
| Do | Lilly gets approval for earlier use of Jaypirca in CLL | ||
| Do | FDA could hike user fees for ex-US drug programmes | ||
| Do | Bayer takes Alport syndrome drug into phase 2 | ||
| Do | Tracy Beth Hoeg will be fifth CDER head this year | ||
| Mi | Appeals court turns Enhertu patent dispute on its head | ||
| Mi | FDA clears trial of 'vectorised' ALS antibody from VectorY | ||
| Mi | AZ uses a priority review voucher for baxdrostat filing | ||
| Mi | FDA takes steps to limit non-human primate testing | ||
| Di | Pazdur to leave FDA, shortly after taking CDER job | ||
| Di | J&J gets EU approval for Imaavy in gMG | ||
| Di | Bayer aims Mirena at women's health issue with no treatment | ||
| Di | FDA doubles down on its push into AI | ||
| Di | Slow recruitment still hitting UK trials, says pharma | ||
| Mo | UK and US agree zero tariffs on pharma - with price rises | ||
| Mo | EMA starts review of 'transformative' bladder cancer therapy | ||
| Mo | Belite plans filing for oral Stargardt drug after phase 3 win | ||
| Mo | Real-world trial of Lilly's tirzepatide starts in UK | ||
| Mo | Is FDA about to restrict vaccination even further? |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .